XTL Biopharmaceuticals to Present at the 9th Annual BIO CEO & Investor Conference

NEW YORK, February 8  /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 9th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an overview of the Company including an overview of Bicifadine, the Company's recently in-licensed late-stage clinical compound for the treatment of neuropathic pain. Mr. Bentsur's presentation will take place on Wednesday, February 14th, 2007 at 3:00 pm Eastern Standard Time, at the Waldorf Astoria Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XTLB&item_id=1475520

An archived version of the webcast will be available following the conclusion of the live presentation.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL).

  Contact:
  Ron Bentsur, Chief Executive Officer
  Tel: [phone]


DATASOURCE: XTL Biopharmaceuticals Ltd



CONTACT:  Contact: Ron Bentsur, Chief Executive Officer, Tel:

[phone]

Copyright